Hepsal

Hepsal is a prescription‑only medication that contains heparin sodium as its active ingredient. It is supplied as an injectable solution intended for intravenous administration. The product is marketed in the European Union and belongs to the anticoagulant drug class, used to reduce the risk of abnormal blood clot formation. Hepsal is typically stored under controlled temperature conditions and requires careful handling by healthcare professionals to maintain sterility and efficacy.

Hepsal is indicated for several clinical situations where prevention or treatment of thrombotic events is required.

- Prevention and treatment of venous thromboembolism (VTE) in medical and surgical patients. - Prophylaxis of deep‑vein thrombosis (DVT) in patients undergoing orthopedic or general surgery. - Management of acute coronary syndromes, including unstable angina and myocardial infarction. - Treatment of confirmed pulmonary embolism (PE) to restore pulmonary perfusion. - Adjunct therapy during extracorporeal circulation procedures such as cardiopulmonary bypass.

Hepsal may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common: - Minor bleeding at the injection site or from mucous membranes (e.g., nosebleeds, gum bleeding). - Small bruising (ecchymosis) around the infusion site. - Transient elevation of liver enzymes. - Mild thrombocytopenia (low platelet count) detected on laboratory testing. - Local irritation or pain at the catheter insertion point.

Serious: - Major hemorrhage, including intracranial or gastrointestinal bleeding. - Heparin‑induced thrombocytopenia (HIT) with a paradoxical risk of clotting. - Severe allergic reactions such as anaphylaxis or urticaria. - Spontaneous spinal or epidural hematoma causing neurologic deficits. - Disseminated intravascular coagulation (DIC) in rare cases.

Before using Hepsal, healthcare providers should evaluate patient‑specific factors and monitor for potential complications.

- Assess bleeding risk, including recent surgery, trauma, or active gastrointestinal ulceration. - Obtain baseline complete blood count, especially platelet count, and repeat monitoring during therapy. - Review renal and hepatic function, as impairment may affect drug clearance. - Avoid use in patients with known hypersensitivity to heparin or pork‑derived products. - Consider alternative anticoagulation in pregnancy unless benefits outweigh risks. - Use caution in elderly patients due to increased bleeding susceptibility.

Hepsal can interact with other medications, altering anticoagulant effects or increasing bleeding risk.

Avoid: - Concurrent use with other anticoagulants (e.g., warfarin, direct oral anticoagulants) without close monitoring. - Combination with antiplatelet agents such as aspirin, clopidogrel, or NSAIDs that amplify bleeding. - Concomitant administration of fibrinolytic agents (e.g., alteplase, streptokinase). - Use with high‑dose corticosteroids that may affect platelet function.

Use with caution: - Non‑steroidal anti‑inflammatory drugs (NSAIDs) at low doses, requiring periodic coagulation assessment. - Certain antibiotics (e.g., vancomycin, ceftriaxone) that may potentiate anticoagulant effect. - Herbal supplements such as ginkgo biloba, garlic, or fish oil that have mild antiplatelet activity. - Proton pump inhibitors that may interfere with platelet aggregation.